The global Hepatitis B Vaccine (Recombinant) market was valued at US$ 1051.4 million in 2022 and is projected to reach US$ 1290.1 million by 2029, at a CAGR of 3.0% during the forecast period. The influence of COVID-19 and the Russia-Ukraine War were considered while estimating market sizes.
Hepatitis B vaccine is a vaccine that prevents hepatitis B.
This report aims to provide a comprehensive presentation of the global market for Hepatitis B Vaccine (Recombinant), with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Hepatitis B Vaccine (Recombinant). This report contains market size and forecasts of Hepatitis B Vaccine (Recombinant) in global, including the following market information:
Global Hepatitis B Vaccine (Recombinant) Market Revenue, 2018-2023, 2024-2030, ($ millions)
Global Hepatitis B Vaccine (Recombinant) Market Sales, 2018-2023, 2024-2030, (K Units)
Global top five Hepatitis B Vaccine (Recombinant) companies in 2022 (%)
In the last several years, Global market of Hepatitis B vaccine developed smoothly, with an average growth rate of -0.32%.
The classification of Hepatitis B vaccine includes Yeast Derived, CHO Derived, and the sales proportion of Yeast Derived in 2019 is about 97%. Hepatitis B vaccine is widely used for Children and Adult. About 84% of Hepatitis B vaccine is used for Children.
Asia-Pacific is the largest consumption place, with a consumption market share nearly 50% in 2019. Following Asia-Pacific, Middle East and Africa is the second largest consumption place with the consumption market share of nearly 31%.
Market competition is intense. GSK, NCPC, Merck, Bio Kangtai, Dynavax, Hissen, etc. are the leaders of the industry, and they hold key technologies and patents, with high-end customers.
We surveyed the Hepatitis B Vaccine (Recombinant) manufacturers, suppliers, distributors and industry experts on this industry, involving the sales, revenue, demand, price change, product type, recent development and plan, industry trends, drivers, challenges, obstacles, and potential risks.
Total Market by Segment:
Global Hepatitis B Vaccine (Recombinant) Market, by Type, 2018-2023, 2024-2030 ($ Millions) & (K Units)
Global Hepatitis B Vaccine (Recombinant) Market Segment Percentages, by Type, 2022 (%)
Global Hepatitis B Vaccine (Recombinant) Market, by Application, 2018-2023, 2024-2030 ($ Millions) & (K Units)
Global Hepatitis B Vaccine (Recombinant) Market Segment Percentages, by Application, 2022 (%)
Global Hepatitis B Vaccine (Recombinant) Market, By Region and Country, 2018-2023, 2024-2030 ($ Millions) & (K Units)
Global Hepatitis B Vaccine (Recombinant) Market Segment Percentages, By Region and Country, 2022 (%)
- North America (United States, Canada, Mexico)
- Europe (Germany, France, United Kingdom, Italy, Spain, Rest of Europe)
- Asia-Pacific (China, India, Japan, South Korea, Australia, Rest of APAC)
- The Middle East and Africa (Middle East, Africa)
- South and Central America (Brazil, Argentina, Rest of SCA)
Competitor Analysis
The report also provides analysis of leading market participants including:
- Key companies Hepatitis B Vaccine (Recombinant) revenues in global market, 2018-2023 (Estimated), ($ millions)
- Key companies Hepatitis B Vaccine (Recombinant) revenues share in global market, 2022 (%)
- Key companies Hepatitis B Vaccine (Recombinant) sales in global market, 2018-2023 (Estimated), (K Units)
- Key companies Hepatitis B Vaccine (Recombinant) sales share in global market, 2022 (%)
Further, the report presents profiles of competitors in the market, key players include:
- GSK
- Merck
- Sanofi Pasteur
- Dynavax Technologies
- LG Life Sciences
- KM Biologics
- Shenzhen Kangtai Biological Products
- Serum Institute
Outline of Major Chapters:
Chapter 1: Introduces the definition of Hepatitis B Vaccine (Recombinant), market overview.
Chapter 2: Global Hepatitis B Vaccine (Recombinant) market size in revenue and volume.
Chapter 3: Detailed analysis of Hepatitis B Vaccine (Recombinant) manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Sales of Hepatitis B Vaccine (Recombinant) in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space of each country in the world.
Chapter 7: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 8: Global Hepatitis B Vaccine (Recombinant) capacity by region & country.
Chapter 9: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 10: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 11: The main points and conclusions of the report.
